Understanding how p53 mutations affect estrogen receptor beta in triple negative breast cancer
Functional Significance of individual p53 mutations in determining the role of estrogen receptor beta in triple negative breast cancer
This study is looking at how certain changes in the p53 gene affect a protein called estrogen receptor beta in triple negative breast cancer, with the hope of finding new treatment options for patients facing this tough-to-treat cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-11034136 on NIH RePORTER |
What this research studies
This research investigates the role of specific mutations in the p53 gene and their impact on the function of estrogen receptor beta (ERβ) in triple negative breast cancer (TNBC). TNBC is a type of breast cancer that lacks common receptors targeted by existing therapies, making it challenging to treat. The study aims to explore how different p53 mutations influence ERβ's behavior, potentially leading to either tumor growth or suppression. By examining the interactions between ERβ and mutant p53, the research seeks to uncover new therapeutic strategies for patients with TNBC.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer, particularly those with known p53 mutations.
Not a fit: Patients with non-triple negative breast cancer or those without p53 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with triple negative breast cancer.
How similar studies have performed: While the specific interactions between p53 mutations and ERβ in TNBC are still being explored, there is growing evidence that understanding these molecular relationships can lead to significant advancements in cancer treatment.
Where this research is happening
Buffalo, United States
- Roswell Park Cancer Institute Corp — Buffalo, United States (Active)
Researchers
- Principal investigator: Das, Gokul M. — Roswell Park Cancer Institute Corp
- Study coordinator: Das, Gokul M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.